1-4 of 4
Carsten U. Niemann
Close
Sort by
Journal Articles

CLL-IPI applied in Binet A CLL: a nationwide cohort study

Emelie C. Rotbain, Caspar da Cunha-Bang, Christian Brieghel, Carsten U. Niemann
Journal: Blood Advances
Blood Adv (2022) 6 (21): 5698–5701.
https://doi.org/10.1182/bloodadvances.2021006259
Published: 2022
Includes: Supplemental data
Journal Articles

Prediction of clinical outcome in CLL based on recurrent gene mutations, CLL-IPI variables, and (para)clinical data

Mehdi Parviz, Christian Brieghel, Rudi Agius, Carsten U. Niemann
Journal: Blood Advances
Blood Adv (2022) 6 (12): 3716–3728.
https://doi.org/10.1182/bloodadvances.2021006351
Published: 2022
Includes: Supplemental data
Journal Articles

The CLL comorbidity index in a population-based cohort: a tool for clinical care and research

Emelie C. Rotbain, Max J. Gordon, Noomi Vainer, Henrik Frederiksen, Henrik Hjalgrim, Alexey V. Danilov, Carsten U. Niemann
Journal: Blood Advances
Blood Adv (2022) 6 (8): 2701–2706.
https://doi.org/10.1182/bloodadvances.2021005716
Published: 2022
Includes: Supplemental data
Journal Articles

Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment

Clinical Trials & Observations
Iris de Weerdt, Tom Hofland, Renate de Boer, Johan A. Dobber, Julie Dubois, Denise van Nieuwenhuize, Mehrdad Mobasher, Fransien de Boer, Mels Hoogendoorn, Gerjo A. Velders, Marjolein van der Klift, Ester B. M. Remmerswaal, Frederike J. Bemelman, Carsten U. Niemann, Sabina Kersting, Mark-David Levin, Eric Eldering, Sanne H. Tonino, Arnon P. Kater
Journal: Blood Advances
Blood Adv (2019) 3 (17): 2642–2652.
https://doi.org/10.1182/bloodadvances.2019000360
Published: 2019
Includes: Supplemental data